Compound Biejia-Ruangan tablets activate the STING-TBK1 pathway to alleviate hepatic fibrosis in alveolar echinococcosis
Microbiology Spectrum · 2026
DOI: 10.1128/spectrum.02115-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Yuyu Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Laboratory Center, Tumor Hospital…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Protein Serine-Threonine Kinases, Echinococcosis, Hepatic, Membrane Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Alveolar echinococcosis (AE) is a lethal parasitic disease that leads to progressive liver fibrosis, a process characterized by the dominance of M2 macrophages in advanced stages. While the compound Biejia-Ruangan tablet (CBRT) has demonstrated efficacy in reversing hepatic fibrosis, its underlying mechanisms in the context of AE-induced fibrosis are not fully understood. This study aimed to investigate the therapeutic potential of CBRT against AE-induced liver fibrosis and to elucidate its mechanisms of action. Serum levels of liver fibrosis markers and cytokines were measured by ELISA. Liver histopathology and collagen deposition were assessed using H&E and Masson’s trichrome staining. Apoptosis in GHA1 hepatocytes was evaluated by flow cytometry. Macrophage migration was analyzed via scratch and Transwell invasion assays. The involvement of the STING-TBK1 signaling pathway was examined through western blotting (WB), immunohistochemistry (IHC), immunofluorescence (IF), and quantitative real-time PCR (qRT-PCR). Livers from Echinococcus multilocularis ( E.m .)-infected mice exhibited severe fibrosis accompanied by significant infiltration of M2 macrophages and upregulated expression of STING-TBK1 pathway components (Arg-1, α-SMA, STING, and TBK1). Treatment with CBRT (1 g/kg) markedly attenuated liver fibrosis in vivo ( P < 0.01) and inhibited the activation of mouse hepatic stellate cells (mHSCs) in vitro . CBRT suppressed the activation of HSCs, partly by upregulating IFN-γ, suppressed apoptosis in GHA1 hepatocytes, and improved hepatocyte function. Mechanistically, CBRT activates the STING-TBK1 signaling pathway, which subsequently suppresses the polarization of macrophages toward the M2 phenotype, thereby alleviating fibrogenesis. This study demonstrates that CBRT alleviates hepatic fibrosis by activating the STING-TBK1 signaling pathway. This activation elicits a shift in macrophage polarization from the pro-fibrotic M2 phenotype towards the M1 phenotype, which subsequently suppresses the activation of hepatic stellate cells and alleviates fibrogenesis. These findings reveal a novel immunomodulatory mechanism of CBRT centered on the STING-TBK1 axis, providing both experimental evidence and a theoretical foundation for its potential application in treating hepatic fibrosis associated with AE. IMPORTANCE This study demonstrates that compound Biejia-Ruangan tablet (CBRT) alleviates Echinococcus multilocularis ( E.m. )-induced hepatic fibrosis by reactivating the suppressed STING-TBK1 signaling pathway in the chronic infection stage, thereby reprogramming macrophage polarization from a pro-fibrotic M2 phenotype toward an M1 phenotype. This work identifies CBRT as a promising immunomodulatory agent that can reverse the Th2/M2-dominated immunosuppressive microenvironment, providing a novel therapeutic strategy for AE and potentially other infection-associated fibrotic diseases. However, further research is required to validate the translational efficacy of CBRT and to define the precise therapeutic window for STING-TBK1 modulation in human fibrotic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Laboratory Center, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang, China.
- Medical Testing Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
- Medical Testing Center, Xinjiang Medical University Affiliated Traditional Chinese Medicine Hospital, Urumqi, Xinjiang, China.
- Basic Medical College of Xinjiang Medical University, Urumqi, Xinjiang, China.
- Medical Testing Center, The Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
ORCID-Profile: Xiumin Ma, Liang Wang
Zitieren
APA
Ma, Y., Zhao, H., Liu, Y., Meng, M., Chen, J., Sun, Y., Fan, B., Zhou, X., Tian, F., Ma, X., & Wang, L. (2026). Compound Biejia-Ruangan tablets activate the STING-TBK1 pathway to alleviate hepatic fibrosis in alveolar echinococcosis. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02115-25
Vancouver
Ma Y, Zhao H, Liu Y, Meng M, Chen J, Sun Y, et al. Compound Biejia-Ruangan tablets activate the STING-TBK1 pathway to alleviate hepatic fibrosis in alveolar echinococcosis. Microbiology Spectrum. 2026. doi:10.1128/spectrum.02115-25
BibTeX
@article{Ma2026,
author = {Ma, Yuyu and Zhao, Hui and Liu, Yumei and Meng, Menggen and Chen, Jiahui and Sun, Yuqin and Fan, Bin and Zhou, Xuan and Tian, Fengmin and Ma, Xiumin and Wang, Liang},
title = {Compound Biejia-Ruangan tablets activate the STING-TBK1 pathway to alleviate hepatic fibrosis in alveolar echinococcosis},
journal = {Microbiology Spectrum},
year = {2026},
doi = {10.1128/spectrum.02115-25}
}
EUVIMED